Idiopathic pulmonary arterial hypertension

Amy L. Firth, Jess Mandel, Jason Yuan

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Despite improved understanding of the pathobiology of pulmonary arterial hypertension (PAH), it remains a severe and progressive disease, usually culminating in right heart failure, significant morbidity and early mortality. Over the last decade, some major advances have led to substantial improvements in the management of PAH. Much of this progress was pioneered by work in animal models. Although none of the current animal models of pulmonary hypertension (PH) completely recapitulate the human disease, they do provide insight into the cellular pathways contributing to its development and progression. There is hope that future work in model organisms will help to define its underlying cause(s), identify risk factors and lead to better treatment of the currently irreversible damage that results in the lungs of afflicted patients. However, the difficulty in defining the etiology of idiopathic PAH (IPAH, previously known as primary pulmonary hypertension) makes this subset of the disease particularly difficult to model. Although there are some valuable existing models that are relevant for IPAH research, the area would value from the development of new models that more closely mimic the clinical pathophysiology of IPAH.

Original languageEnglish (US)
Pages (from-to)268-273
Number of pages6
JournalDMM Disease Models and Mechanisms
Volume3
Issue number5-6
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Animal Models
Animals
Heart Failure
Morbidity
Lung
Mortality
Research
Familial Primary Pulmonary Hypertension
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)

Cite this

Idiopathic pulmonary arterial hypertension. / Firth, Amy L.; Mandel, Jess; Yuan, Jason.

In: DMM Disease Models and Mechanisms, Vol. 3, No. 5-6, 05.2010, p. 268-273.

Research output: Contribution to journalArticle

Firth, Amy L. ; Mandel, Jess ; Yuan, Jason. / Idiopathic pulmonary arterial hypertension. In: DMM Disease Models and Mechanisms. 2010 ; Vol. 3, No. 5-6. pp. 268-273.
@article{647290a81f6b41adadd9c52834f9bbc6,
title = "Idiopathic pulmonary arterial hypertension",
abstract = "Despite improved understanding of the pathobiology of pulmonary arterial hypertension (PAH), it remains a severe and progressive disease, usually culminating in right heart failure, significant morbidity and early mortality. Over the last decade, some major advances have led to substantial improvements in the management of PAH. Much of this progress was pioneered by work in animal models. Although none of the current animal models of pulmonary hypertension (PH) completely recapitulate the human disease, they do provide insight into the cellular pathways contributing to its development and progression. There is hope that future work in model organisms will help to define its underlying cause(s), identify risk factors and lead to better treatment of the currently irreversible damage that results in the lungs of afflicted patients. However, the difficulty in defining the etiology of idiopathic PAH (IPAH, previously known as primary pulmonary hypertension) makes this subset of the disease particularly difficult to model. Although there are some valuable existing models that are relevant for IPAH research, the area would value from the development of new models that more closely mimic the clinical pathophysiology of IPAH.",
author = "Firth, {Amy L.} and Jess Mandel and Jason Yuan",
year = "2010",
month = "5",
doi = "10.1242/dmm.003616",
language = "English (US)",
volume = "3",
pages = "268--273",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "5-6",

}

TY - JOUR

T1 - Idiopathic pulmonary arterial hypertension

AU - Firth, Amy L.

AU - Mandel, Jess

AU - Yuan, Jason

PY - 2010/5

Y1 - 2010/5

N2 - Despite improved understanding of the pathobiology of pulmonary arterial hypertension (PAH), it remains a severe and progressive disease, usually culminating in right heart failure, significant morbidity and early mortality. Over the last decade, some major advances have led to substantial improvements in the management of PAH. Much of this progress was pioneered by work in animal models. Although none of the current animal models of pulmonary hypertension (PH) completely recapitulate the human disease, they do provide insight into the cellular pathways contributing to its development and progression. There is hope that future work in model organisms will help to define its underlying cause(s), identify risk factors and lead to better treatment of the currently irreversible damage that results in the lungs of afflicted patients. However, the difficulty in defining the etiology of idiopathic PAH (IPAH, previously known as primary pulmonary hypertension) makes this subset of the disease particularly difficult to model. Although there are some valuable existing models that are relevant for IPAH research, the area would value from the development of new models that more closely mimic the clinical pathophysiology of IPAH.

AB - Despite improved understanding of the pathobiology of pulmonary arterial hypertension (PAH), it remains a severe and progressive disease, usually culminating in right heart failure, significant morbidity and early mortality. Over the last decade, some major advances have led to substantial improvements in the management of PAH. Much of this progress was pioneered by work in animal models. Although none of the current animal models of pulmonary hypertension (PH) completely recapitulate the human disease, they do provide insight into the cellular pathways contributing to its development and progression. There is hope that future work in model organisms will help to define its underlying cause(s), identify risk factors and lead to better treatment of the currently irreversible damage that results in the lungs of afflicted patients. However, the difficulty in defining the etiology of idiopathic PAH (IPAH, previously known as primary pulmonary hypertension) makes this subset of the disease particularly difficult to model. Although there are some valuable existing models that are relevant for IPAH research, the area would value from the development of new models that more closely mimic the clinical pathophysiology of IPAH.

UR - http://www.scopus.com/inward/record.url?scp=77952192354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952192354&partnerID=8YFLogxK

U2 - 10.1242/dmm.003616

DO - 10.1242/dmm.003616

M3 - Article

C2 - 20427556

AN - SCOPUS:77952192354

VL - 3

SP - 268

EP - 273

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 5-6

ER -